TRUS Destekli Prostat Biyopsisi için Sanal MR/Ultrason Rehberliği
Oncological Imaging and the Role of Multiparametric Magnetic Resonance Imaging (mMRI) in the Detection of Prostate Cancer, Guided Biopsies, and Therapy
"Multiparametric MRI is essential for clinical decision making in prostate cancer comprising planning and guidance of biopsy, of radical and focal therapies as well as of active surveillance."2
Professor Heinz-Peter Schlemmer
German Cancer Research Center, Heidelberg, Germany
"Multiparametric MRI is now being incorporated into many guidelines for the detection of prostate cancer particularly in men with persistently raised PSA levels and negative systematic transrectal prostate biopsies, who are considered to harbor cancer that has not yet been diagnosed. Beyond detection of suspected lesions, better targeted biopsies from cancer suspicious regions at highest risk of harbouring the most aggressive lesion is needed.”2
Professor Anwar R. Padhani
Mount Vernon Cancer Center and Institute of Cancer Research,
Royal Marsden Hospital, London , United Kingdom
Clinical Guidelines for MR Imaging in Prostate Cancer3,4
According to prostate cancer guidelines published by the European Association of Urology in 2014, correlation with radical prostatectomy specimens has shown that multiparametric MRI has excellent sensitivity for detecting aggressive cancers with a Gleason score greater than 7. In addition to detecting these aggressive cancers, mMRI is particularly good at accurately detecting anterior tumors, which are not usually detected by systematic biopsies. A (targeted) repeat prostate biopsy under mMRI guidance is recommended to detect tumors that may have been missed by systematic biopsies.5
Level of evidence: 2b. Grade of recommendation: B.
Siemens offers a fully integrated solution for all aspects of prostate cancer diagnosis – to ensure not only a precise and early diagnosis but also the best possible care. The ArtemisTM solution by Eigen provides proven and effective virtual MR guidance for TRUS-assisted prostate biopsy.
1The information shown herein refers to products of 3rd party manufacturer’s (ArtemisTM, Eigen) and thus are in their regulatory responsibility. Please contact the 3rd party manufacturer for further information.
2The outcomes achieved by customers described herein were achieved under the customer’s unique setting. Since there is no “typical” hospital and many variables exist (e.g., hospital size, case mix, level of IT adoption), there can be no guarantee that others will achieve the same results.
3Barentz, Jelle O., et al.; ESUR prostate MR guidelines 2012. European Radiology, DOI 10.1007/s00330-011-2377-y
4The information presented is for illustration only and is not intended to be relied upon by the reader for instruction as to the practice of medicine. Healthcare practitioners reading this information are reminded that they must use their own learning, training, and expertise in dealing with their individual patients. This material does not substitute for that duty and is not intended by Siemens Healthcare to be used for any purpose in that regard.
5Mottet, N. et al.; Guidelines on Prostate Cancer, European Association of Urology, 2014